Over 15,400 NHS patients a year could benefit from new medicines after NICE threshold rise

Early evidence shows that more than 15,400 NHS patients a year could gain access to new medicines they may otherwise have gone without, in just the first five months following a historic change in how NICE values innovation.

The ABPI’s latest ‘Continuous NICE Implementation Evaluation’ (CONNIE) report provides evidence of what the higher threshold, introduced in April 2026, means for NHS patients.[1] The threshold was raised from £20,000–£30,000 to £25,000–£35,000 per quality-adjusted life year, the measure NICE uses to weigh a medicine’s benefits against its cost.[2]

Of the 20 medicine appraisals in the report that concluded after the change, half saw a better outcome for patients as a result.

For nine treatments, companies said NICE may not have recommended the medicine under the old threshold, with six reporting they would not have been able to launch the medicine in the UK at all under the previous threshold. In the tenth, the change extended access to a wider group of patients than would otherwise have benefited. [3]

The new medicines now made available to the NHS span a range of serious and life-limiting conditions. Seven of the 10 medicines are for cancer patients - including brain tumours that could affect young children, late-stage breast cancer, and advanced stomach cancers for people with limited treatment options. Two were for cardiovascular conditions, and one was for an endocrine condition.

Based on estimates of eligible patients, together they could benefit an additional 15,426 patients every year. The figures broadly align with government data published in July, which showed that nine additional medicines were approved in England and Wales because of the threshold change. Eight of those nine are captured in the CONNIE data, meaning at least 11 medicines are now available to NHS patients because of the higher threshold. [4]

Victoria Jordan, Executive Director, Patient Access at the ABPI, said: “These are the first signs of what the higher threshold means for NHS patients, and companies’ ability to launch innovative medicines in the UK. More than 15,4 00 patients a year could now be offered medicines that might otherwise not have been available to them. For each of those patients and their families, a new treatment can mean more time, better quality of life and greater independence. The task now is to make sure these early gains are sustained, that the full threshold range is used to support access to new medicines, and that the benefits for patients and the NHS are realised through rapid and equitable adoption.”

The report, which draws on company feedback from 183 completed NICE appraisals, also finds that the full benefit of the higher threshold is not yet guaranteed:

  • the top of the threshold range remains under-used, with more than half (54 per cent) of appraisals decided at the lower end of the range or below it

  • the share of appraisals where final guidance is delayed by more than a year has risen steadily and now stands at around one in five, keeping patients waiting longer for a decision

  • disagreement over how severe a condition is judged to be, which can determine whether a medicine is recommended, is far more common for rare conditions (17 per cent of appraisals) than common ones (3 per cent)

The ABPI will continue to track the impact of the threshold change through CONNIE and work with NICE, government and the NHS to ensure the benefits continue and reach patients with all types of conditions.

TAGS
  • Access
  • Commercial
  • Evaluation
  • Health and Access to Medicines
  • Medicines sales
  • NICE
  • Pricing

Last reviewed date: 19 November 2026

Next review date: 19 November 2029

[1] ABPI, ‘Reviewing implementation in practice of the NICE Health Technology Evaluation Manual – CONNIE November 2026’. CONNIE collects feedback from pharmaceutical companies on the completion of their NICE appraisals. This is the fifth report in the series and covers 183 appraisals completed between August 2022 and August 2026, around 45 per cent of all appraisals using NICE’s current methods over that period.
[2] NICE’s cost-effectiveness threshold increased in April 2026 from £20,000–£30,000 per quality-adjusted life year (QALY) to £25,000–£35,000 per QALY, the first change in more than two decades. A QALY combines length and quality of life into a single measure: one QALY is one year in full health. NICE, ‘Changes to NICE’s cost-effectiveness thresholds’.
[3] Twenty appraisals in the CONNIE data had final guidance published after the threshold increase, between 1 April and 5 August 2026. Findings are based on company-reported feedback. Patient numbers are company estimates of the number of additional NHS patients eligible for treatment each year, not the number treated. CONNIE does not capture every NICE appraisal, so some medicines affected by the threshold change will not be included. The period covered also included interim arrangements, including a pause in appraisals where a positive recommendation would have been enabled by the threshold increase, so may not reflect the longer-term pattern.
[4] Department of Health and Social Care, ‘NHS patients get faster access to medicines under new pilots’, July 2026

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.